Jane Street Group LLC lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 37.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,165 shares of the company's stock after selling 137,906 shares during the quarter. Jane Street Group LLC owned approximately 0.16% of Denali Therapeutics worth $4,670,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Rhumbline Advisers raised its stake in Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Denali Therapeutics by 0.8% in the fourth quarter. The Manufacturers Life Insurance Company now owns 208,521 shares of the company's stock worth $4,250,000 after buying an additional 1,702 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after acquiring an additional 2,436 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.
Denali Therapeutics Stock Down 0.3 %
NASDAQ:DNLI opened at $14.39 on Friday. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The stock's fifty day moving average is $14.27 and its two-hundred day moving average is $20.04. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -5.21 and a beta of 1.49.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter in the prior year, the firm posted ($0.68) earnings per share. On average, sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have weighed in on DNLI. Oppenheimer decreased their target price on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Robert W. Baird reduced their price objective on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. Finally, B. Riley reissued a "buy" rating and set a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of "Buy" and an average target price of $33.79.
Get Our Latest Analysis on Denali Therapeutics
Denali Therapeutics Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Featured Articles
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
